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Background: A subpopulation of tumor cells with distinct stem-like properties (cancer stem-like cells, CSCs) may be
responsible for tumor initiation, invasive growth, and possibly dissemination to distant organ sites. CSCs exhibit a
spectrum of biological, biochemical, and molecular features that are consistent with a stem-like phenotype, including
growth as non-adherent spheres (clonogenic potential), ability to form a new tumor in xenograft assays, unlimited
self-renewal, and the capacity for multipotency and lineage-specific differentiation. PKCδ is a novel class serine/
threonine kinase of the PKC family, and functions in a number of cellular activities including cell proliferation, survival or
apoptosis. PKCδ has previously been validated as a synthetic lethal target in cancer cells of multiple types with aberrant
activation of Ras signaling, using both genetic (shRNA and dominant-negative PKCδ mutants) and small molecule
inhibitors. In contrast, PKCδ is not required for the proliferation or survival of normal cells, suggesting the potential
tumor-specificity of a PKCδ-targeted approach.
Methods: shRNA knockdown was used validate PKCδ as a target in primary cancer stem cell lines and stem-like cells
derived from human tumor cell lines, including breast, pancreatic, prostate and melanoma tumor cells. Novel and
potent small molecule PKCδ inhibitors were employed in assays monitoring apoptosis, proliferation and clonogenic
capacity of these cancer stem-like populations. Significant differences among data sets were determined using
two-tailed Student’s t tests or ANOVA.
Results: We demonstrate that CSC-like populations derived from multiple types of human primary tumors, from
human cancer cell lines, and from transformed human cells, require PKCδ activity and are susceptible to agents which
deplete PKCδ protein or activity. Inhibition of PKCδ by specific genetic strategies (shRNA) or by novel small molecule
inhibitors is growth inhibitory and cytotoxic to multiple types of human CSCs in culture. PKCδ inhibition efficiently
prevents tumor sphere outgrowth from tumor cell cultures, with exposure times as short as six hours. Small-molecule
PKCδ inhibitors also inhibit human CSC growth in vivo in a mouse xenograft model.
Conclusions: These findings suggest that the novel PKC isozyme PKCδ may represent a new molecular target for
cancer stem cell populations.
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Much recent data supports the model that a subpopu-
lation of tumor cells with distinct stem-like properties is
responsible for tumor initiation, invasive growth, and pos-
sibly dissemination to distant organ sites [1-3]. This small
subpopulation of cells can divide asymmetrically, produ-
cing an identical daughter cell and a more differentiated
cell, which, during their subsequent divisions, generate the
vast majority of tumor bulk [4,5]. A number of names
have been used to identify this subpopulation, including
“cancer progenitor cells,” “cancer stem cell-like cells,” and
“cancer-initiating cells,” but the term “cancer stem cell”
(CSC) has received wide acceptance [6].
The first identification of CSCs in solid tumors was
made in 2003, when CSCs were identified and isolated
from breast cancers using CD44 and CD24 markers [7].
Subsequently, CSCs have been identified in a variety of
solid tumors, including glioblastoma [8-10], osteosar-
coma [11], chondrosarcoma [12], prostate cancer [13],
ovarian cancer [14-18], gastric cancer [19], lung cancer
[20,21], colon cancer [22-25], pancreatic cancer [26,27],
melanoma [28-30], head and neck cancer [31], and
others. CSCs isolated from these different tumor types
share some common characteristics including drug re-
sistance, ability to repopulate tumors, and asymmetric
division.
CSC exhibit a spectrum of biological, biochemical, and
molecular features that are consistent with a stem-like
phenotype, including growth as non-adherent spheres
(clonogenic potential), superior ability to form a new
tumor in in vivo xenograft assays, unlimited self-renewal,
and the capacity for multipotency and lineage-specific dif-
ferentiation [1,32-35]. In particular, CSCs are able to form
colonies from a single cell more efficiently than their
progeny [36] and to grow as spheres in non-adherent,
serum-free culture conditions [37]. Sphere formation in
non-adherent cultures has been used as a surrogate
in vitro method for detecting CSCs from primary human
tumors [8,20,25,38,39]. CSC populations also variably
exhibit “stem cell-like” markers, such as Nanog, Sox2,
aldehyde-dehydrogenase positivity, and telomerase.
Chemoresistance is also considered a hallmark of CSCs
[6,40]. They characteristically survive chemo- and radio-
therapeutic interventions [41] and may thus be respon-
sible for both tumor relapse and metastasis [42]. CSCs are
often innately less sensitive to treatment than are the bulk
of the tumor cells that they generate [43,44]. These fea-
tures support the hypothesis that CSCs are the cell sub-
population that is most likely responsible for treatment
failure and cancer recurrence [32].
Aberrant activation of Ras signaling, either through mu-
tation of the Ras genes themselves, or through constitutive
upstream or downstream signaling, is very common in
solid tumors. We have previously identified the proteinkinase C delta (PKCδ) isozyme as a Ras synthetic lethal
interactor [45-48]. PKCδ is a serine/threonine kinase of
the PKC family, a member of the novel class, and func-
tions in a number of cellular activities including cell pro-
liferation, survival or apoptosis [49]. However, PKCδ is
not required for the proliferation of normal cells, and
PKCδ-null animals develop normally and are fertile, sug-
gesting the potential tumor-specificity of a PKCδ-targeted
approach [50]. PKCδ was validated as a target in cancer
cells of multiple types with aberrant activation of Ras sig-
naling, using both genetic (siRNA and dominant-negative
PKCδ) and small molecule inhibitors [45], by our group
[45,47] and later by others [51,52]. “Ras-dependency” in
these tumors was not required for these synthetic-lethal
cytotoxic effects [45,46]. Tumors with aberrant activation
of the PI3K pathway or the Raf-MEK-ERK pathway in the
setting of wild-type RAS alleles have also been shown to
require PKCδ activity for proliferation or survival [47,48].
In this report, we demonstrate that CSC-like cell pop-
ulations derived from multiple types of human primary
tumors, from human cancer cell lines, and from trans-
formed human cells require PKCδ activity and are




MCF10A and MCF10C breast cell lines were derived at the
Barbara Ann Karmanos Cancer Institute (Detroit, MI) and
maintained in DMEM-F/12 medium containing 5% heat-
inactivated horse serum, 10 μg/mL insulin, 20 ng/mL epi-
dermal growth factor, 0.1 μg/mL cholera enterotoxin, and
0.5 μg/mL hydrocortisone [53,54]. Breast cancer cell lines
MCF7, Hs587T, and MDA231 were purchased from ATCC,
and were propagated in 10% fetal bovine serum (Invitrogen,
Grand Island, NY); Dulbecco’s Modification of Earle’s Media
(Cellgro, Herndon, VA); 2 mM L-Glutamine (Invitrogen);
200 U Penicillin/ml; 200 μg Streptomycin/ml (Invitrogen).
Human breast cancer stem cells (BCSC: CD133+, CD44+,
SSEA3/4+, Oct4+, Alkaline Phosphatase+, Aldehyde De-
hydrogenase+, Telomerase+), pancreatic cancer stem cells
(PCSC: CD44+, CD133+, SSEA3/4+, Oct4+, Alkaline Phos-
phatase+, Aldehyde Dehydrogenase+, Telomerase+, and
Nestin+), and prostate cancer stem cells (PrCSC: CD44+,
CD133+, SSEA3/4+, Oct4+, alkaline phosphatase+, alde-
hyde dehydrogenase+, and telomerase+) were purchased
from Celprogen (San Pedro, CA), and cultured using spe-
cialized media and tissue culture plastic and matrix, to
preserve their CSC phenotype, according to the manufac-
turer’s instructions.
Reagents
Rottlerin was purchased from (EMD Biosciences, San
Diego, CA). The PKCδ inhibitor KAM1 was previously
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cribed elsewhere [55]. Briefly, 9-(2-(trifluoro-λ4-boranyl)
ethyl)-9H-carbazole, potassium salt (Molander Salt 1), 6-
bromo-2,2-dimethyl-2H-chromene-8-carbaldehyde, 64.0 mg
(0.213 mmol, 1 equiv.), PdCl2(dppf)-CH2Cl2, and anhy-




Tumor self-renewing and anchorage-independent sphe-
roids were obtained by culturing breast cancer cells
MCF7, Hs587T and MDA231; melanoma cells SBcl2 and
FM6; human breast cancer stem cells and pancreatic can-
cer stem cells in stem cell-selective conditions according
to the manufacturer’s instructions (StemCell Technolo-
gies, Tukwila, WA). Briefly, cancer and cancer stem cells
were propagated in 6-well ultra-low adherent plates
(Corning) in Complete MammoCult Medium (Human) by
adding 50 mL of MammoCult Proliferation Supplements
to 450 mL of MammoCult Basal Medium (StemCell
Technologies). The following were added to obtain
Complete MammoCult Medium: 4 ug/mL Heparin (Stem-
Cell Technologies), 0.48 μg/mL hydrocortisone (StemCell
Technologies), 200 U penicillin/ml; and 200 μg strepto-
mycin/ml (Invitrogen).
Flow cytometry
Cell staining for CD24 or CD44: MCF7 and MCF7
spheres, Hs587T and Hs587T spheres, MDA231 and
MDA231 spheres, breast cancer stem cells and breast can-
cer stem cell spheres were collected and stained or dual-
stained with Fluorescein isothiocyanate (FITC)-anti-CD24
and (PerCP-Cy)-anti-CD44 (BD Pharmingen, San Diego,
CA) monoclonal antibody (mAbs) for 30 min on ice. The
stained cancer cells and sphere populations were analyzed
by FACSCAN analysis.
Clonogenic assays
100,000 cells were seeded on 100 mm dishes with 10 ml
media per dish [47]. On day 4, cells were treated with a
PKCδ inhibitor or vehicle control for either 6, 18, 24 or
48 hours. Cells were trypsinized; counted via the trypan
blue exclusion method in order to determine the num-
ber of live cells in the sample, and 300 live cells were
seeded in triplicate onto 6-well plates. Cells were moni-
tored for appropriate colony size and re-fed every three
to four days. At Day 15, cells were stained with ethidium
bromide [56] and counted using UVP LabWorks soft-
ware (Waltham, MA).
Cell proliferation assays
Cell proliferation was assessed using an MTT [3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay(Roche, Mannheim, Germany). The number of viable cells
growing in a single well on a 96-well microtiter plate was
estimated by adding 10 μl of MTT solution (5 mg/ml in
phosphate-buffered saline [PBS]). After 4 h of incubation
at 37°C, the stain was diluted with 100 μl of dimethyl sulf-
oxide. The optical densities were quantified at a test wave-
length of 570 nm and a reference wavelength of 690 nm
on a multiwell spectrophotometer. In some assays, MTS
was used as substrate (Promega, Madison, WI), and the
absorbance of the product was monitored at 490 nm. Cell
enumeration was carried out using a hemocytometer, and
viable cells identified by trypan blue exclusion.
PKC kinase activity assays
Assays were carried out using recombinant PKCδ or
PKCα, (Invitrogen) and the Z-lyte Kinase Assays (Invitro-
gen) with a “PKC-kinase-specific” peptide substrate. FRET
interactions produce a change in fluorescence (ex455/
ex520) upon phosphorylation. The kit was used according
to the manufacturer’s instructions.
Cytotoxicity assay
LDH release was assessed by spectrophotometrically
measuring the oxidation of NADH in both the cells and
media. Cells were seeded in 24-well plates, and exposed to
PKCδ inhibitors or vehicle. After different times of expo-
sure, cytotoxicity was quantified by a standard measure-
ment of LDH release with the use of the LDH assay kit
(Roche Molecular Biochemicals) according to the manu-
facturer’s protocol. Briefly, total culture medium was
cleared by centrifugation. For assay of released LDH,
supernatants were collected. To assess total LDH in cells,
Triton X-100 was added to vehicle (control) wells to re-
lease intracellular LDH. LDH assay reagent was added to
lysates or supernatants and incubated for up to 30 min at
room temperature in dark, the reaction was stopped, and
the absorbance was measured at 490 nm. The percentage
of LDH release was then calculated as the LDH in the
supernatants as a fraction of the total LDH.
Immunoblot analyses
Levels of proteins were measured and quantitated in cells
as we have previously reported [45]. Harvested cells were
disrupted in a buffer containing 20 mM Tris (pH 7.4),
0.5% NP-40, and 250 mM NaCl with protease and phos-
phatase inhibitors. Total protein (40 μg) was separated on
10% SDS-polyacrylamide gels and transferred to nitrocel-
lulose membranes or PVDF membranes. Membranes were
blocked overnight and probed with affinity-purified anti-
bodies against: PKCδ (BD Transduction Labs, San Jose,
CA), or β-actin or α-tubulin (Sigma Aldrich, St. Louis,
MO). Antibodies against human ERK, phospho-ERK1/2
(Thr202/Tyr204), AKT and phospho-AKT (Ser473), JNK
and phospho-JNK (Thr183/Tyr185) were purchased from
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were incubated with horseradish peroxidase-conjugated
secondary antibodies and visualized using the Amersham
enhanced chemiluminescence ECL system, and quanti-
tated by digital densitometry.
Down-regulation of PKC by shRNA and lentiviral vectors
shRNA duplexes for PKCδ (shRNAs) were obtained from
Qiagen (Valencia, Ca). The shRNA sequences for targeting
PKCδ and the corresponding scrambled shRNAs used as
negative controls were previously described [47]. The len-
tiviral vectors were previously described [46]. After infec-
tion of cells with the vectors, one aliquot was utilized in
proliferation assays and a parallel aliquot was subjected to
immunoblotting to assay the efficiency of the knockdown.
Xenograft studies
These studies were performed with the approval of the
Institutional Animal Care and Use Committee of Boston
University. Breast cancer stem cells (2 × 105) grown from
a metastatic tumor were suspended in human breast
cancer stem cell complete growth media (Celprogen, San
Pedro, CA) and injected subcutaneous into the right flank
of female J:NU mice (The Jackson Laboratory, ME) under
anesthesia. After palpable tumors developed, the mice were
divided into two groups of animals. The control group re-
ceived daily intraperitoneal injections of vehicle (DMSO)
while the treatment group received daily intraperitoneal
injections of a PKCδ inhibitor (rottlerin 5,000 μg/kg) for
15 days. The length and width of tumors were measured
with a vernier caliper and tumor volumes were calculated.
Survival was calculated as the day tumors reached the
maximum size allowed by the protocol (2 cm diameter).
Statistical analysis
Experiments were carried out in triplicate for all experi-
mental conditions. Data are shown as mean ± SD. Where
applicable, a two-tailed Student’s t test or ANOVA was
performed on the means of two sets of sample data and
considered significant if p ≤ 0.05.
Results
Inhibition of PKCδ is growth-inhibitory and cytotoxic in
human prostate and pancreatic cancer stem cells
The sensitivity of human cancer stem cell cultures to in-
hibition of PKCδ was first examined using shRNA me-
thodology to specifically and selectively knockdown
transcripts for this PKC isozyme and thereby specifically
validate PKCδ as a target in CSCs. Cell cultures derived
from a primary human pancreatic adenocarcinoma
(PCSC) and from a primary human prostate adenocar-
cinoma (PrCSC), isolated by phenotypic markers, were
studied. These cells were characterized as “stem-like” by
a number of criteria. The PCSC and the PrCSC cultureswere CD44+, CD133+, Nanog+, Sox2+, aldehyde de-
hydrogenase+, and telomerase+. The PCSC cultures were
also Nestin+. Both cell types were tumorigenic at <1000
cells in xenograft assays in SCID mice, and also formed
tumor spheroids at high efficiency. Lentiviral vectors ex-
pressing PKCδ-specific shRNAs (PKCδ-shRNA), which
we have previously shown to be specific for the PKCδ
isozyme among all the other PKC isozymes [45-47], were
used to deplete PKCδ levels in the cells. A vector
containing a scrambled shRNA (sc-shRNA) served as a
control. Specific knockdown of PKCδ by shRNA was
growth-inhibitory in both the human prostate (PrCSC)
and pancreatic (PCSC) cancer stem cells, with significant
effects observed at early as 24 hr after infection, and
progressing up to 72 hr (Figure 1A). The non-targeted
lentiviral vector (sc-shRNA) generated modest but re-
producible effects on cell growth over time, as we have
observed in prior reports [45-47]. Cytotoxic effects of
PKCδ depletion on the PCSC and PrCSC cultures were
assessed by quantitating release of cellular LDH. Sig-
nificant cytotoxicity was elicited by the PKCδ-specific
shRNA as early as 24 hr after infection, with LDH re-
lease approaching the maximum possible levels by 72 hr.
The effects of the scrambled shRNA on LDH release did
not differ from those of the infection vehicle alone at
any time point (Figure 1B). Efficient knockdown of
the PKCδ isozyme was verified by immunoblotting
(Figure 1C).
While the specificity of shRNA is essential for validation
of a target, small-molecule enzyme inhibitors are more
likely than shRNA to translate towards clinical application.
We therefore next examined the effects of existing and
novel small molecule inhibitors of PKCδ. Rottlerin, a na-
tural product, has been identified as a PKCδ inhibitor for
many years [47], with an in vitro IC50 of approximately
5 μM in our kinase assays (Table 1), in good agreement
with the literature [57,58] (although it also exerts inhibi-
tory effects on certain non-PKC kinases at concentrations
comparable to the IC50 for PKCδ [59]). We and others
have shown that rottlerin, at the concentrations employed
herein, is not cytostatic or cytotoxic to normal primary
cells or cell lines, and is well-tolerated when administered
orally or intraperitoneally to mice (see also the studies on
normal human breast epithelial cells and the in vivo stu-
dies later in this report) [45-47]. Exposure of PCSC and
PrCSC cultures to rottlerin produced a significant dose-
dependent inhibition of proliferation as early as 24 hr after
exposure (Figure 2A). Similarly, rottlerin induced cytoto-
xicity in both CSC cultures in a dose-dependent fashion,
as assessed by LDH release (Figure 2B). The duration of
PKCδ inhibition required to irreversibly prevent CSC
proliferation was next assessed. Exposure to rottlerin
efficiently decreased the clonogenic capacity of PCSC.
Eighteen hr of exposure to rottlerin, followed by washout,
Figure 1 Effects of PKCδ knockdown by shRNA on proliferation and viability of human pancreatic (PCSC) and prostate (PrCSC) cancer
stem cell cultures. (A) PCSC and PrCSC cells were grown to 50% confluence in 96-well plates and then infected with PKCδ-shRNA-expressing
lentivirus vector or a lentiviral vector containing a scrambled shRNA (sc-shRNA). The corresponding equivalent volumes of diluent used for infection
served as vehicle controls (Vehicle). 24 and 72 hr after transfection, cell mass was evaluated by MTS assay. Error bars represent SEM. p values for
comparison between control (scrambled shRNA) and PKCδ-shRNA effects on cell number reached significance at 24 hr of exposure (p < 0.001) for all
cell lines, and remained significant at the 72 hr time point. (B) PCSC and PrCSC cells were grown to 50% confluence in 96-well plates and then infected
with PKCδ-shRNA or scrambled shRNA (sc-shRNA) expressing lentiviruses. The corresponding equivalent volumes of diluent were used as vehicle
controls (Vehicle). After 24 and 72 hr of infection, cell cytotoxicity was evaluated by LDH-release assay. Total maximal LDH release was assigned the
arbitrary value of 100% (Control). Error bars represent SEM. p values for comparison between effects on LDH release for cells infected with scrambled
shRNA-expressing vectors compared to PKCδ-shRNA vectors reached significance at 24 hr of exposure (p < 0.01) for all cell lines, and remained
significant at the 72 hr time point. (C) Immunoblot analysis of PKCδ protein levels in the same cell lines 72 hr after infection with PKCδ-targeting shRNA
expressing lentiviral vectors (+) or scrambled shRNA (−). PKCδ-targeted shRNA vectors efficiently reduced PKCδ protein expression. Immunoblotting
with a β-actin antibody after stripping the blots served as a loading control.
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by 40%, and increasing the duration of the exposure to
48 hr reduced the clonogenic potential by more than 90%
(Figure 2C).
As previously reported, we have sought to develop
novel PKCδ-inhibitory molecules with greater specificity
for PKCδ compared to essential PKC isozymes, such as
PKCα, using pharmacophore modeling and structure-Table 1 Comparison of three generations of PKCδ
inhibitors
Generation PKCδIC50 PKCαIC50 PKCδ/PKCα
Selectivity ratio
1 3 μM 75 μM 28-fold
2 2 μM 157 μM 56-fold
3 0.05 μM 50 μM 1000-foldactivity relationships (SAR) [47]. We designed and syn-
thesized a set of analogs based on this strategy. In this
2nd generation of PKCδ inhibitors, the “head” group
(carbazole portion) was made to resemble that of stauros-
porine, a potent general PKC inhibitor, and other bisindoyl
maleimide kinase inhibitors, with two other domains
(cinnamate side chain and benzopyran) conserved from
the rottlerin scaffold to preserve isozyme specificity. The
first such chimeric molecule reported, KAM1 (Figure 2D),
was indeed active, like staurosporine, but was also
more PKCδ-specific, and showed potent activity against
Ras-mutant human cancer cells in culture and in vivo
animal models, while not producing cytotoxicity in non-
transformed cell lines [47]. KAM1 induced cytotoxicity as
assessed by LDH release in a dose-dependent fashion in
both PCSC and PrCSC cultures at concentrations as low
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Figure 2 Effects of PKCδ inhibitors on human cancer stem cells. (A) PCSC and PrCSC cells at 80% confluence were exposed to rottlerin. DMSO
served as vehicle control (Vehicle). After 24 and 72 hr of exposure, cell mass was evaluated by MTT assay. Control values were normalized to 100%. p
values for comparison between treatments reached significance at 24 hr of exposure (p≤0.01) for both cell types, and remained significant at 72 hr.
(B) PCSC and PrCSC cells at 50% confluence were exposed to rottlerin. Cytotoxicity was evaluated by LDH-release assay. Total maximal LDH release
was assigned the arbitrary value of 100% (Control). p values for comparison between effects of treatments on LDH release reached significance at 24
hr of exposure (p<0.01) for both cell types, and remained significant at 72 hr. (C) Effects of PKCδ inhibitor on tumor cell clonogenic capacity. PCSC
were exposed to vehicle or rottlerin (10 μM) for 6, 18, 24, or 48 hr. Viable cells were enumerated and re-plated in media without inhibitor, and colony
numbers were quantitated 15 days later. p values for comparison of treatment effects on clonogenic capacity reached significance (p=0.005) at 18 hr
of exposure and remained significant for all subsequent exposure times. The insert is a photograph of stained colonies on plates. (D) Structures of
staurosporine, rottlerin, second-generation (KAM1) and third-generation (BJE6-106) derivatives. (E) PCSC and PrCSC cells at 50% confluence were
exposed to KAM1 at the indicated concentrations. DMSO served as vehicle control (Vehicle). Cytotoxicity was evaluated by LDH-release assay, as in
panel B. p values for comparison between treatment effects on LDH release reached significance at 24 hr of exposure to 2.5 μM KAM1 for PCSC cells
and at 10 μM for PrCSC (p≤0.01), and remained significant at 72 hr for all concentrations of KAM1. Error bars represent SEM.
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signed thirty-six new 3rd-generation analogs. The syn-
thetic chemistry platform that was used to prepare KAM1
was modified to synthesize these additional analogs, which
were then tested for biochemical and cellular activity. The
PKCδ-inhibitory activity and isozyme-specificity of this 3rd
generation was quantitated in vitro. A number of these 3rdgeneration analogs demonstrated significant increases in
potency and isozyme specificity over rottlerin (1st gene-
ration) and KAM1 (2nd generation). The new compound
selected for study in this report, BJE6-106, is much more
potent than rottlerin. BJE6-106 has an (in vitro) PKCδ
IC50 in the range of 0.05 μM, compared to 3 μM for
rottlerin (Table 1), is approximately 1000-fold more
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cytotoxic activity against cells with aberrant Ras signaling
at nM concentrations [55].
The activity of the 3rd generation PKCδ inhibitor
BJE6-106 on the growth of PCSC cells in culture was
compared to rottlerin. BJE6-106 inhibited the growth of
PCSC cultures at concentrations as low as 0.1 μM, and
had an (in culture) IC50 of approximately 0.5 μM at
48 hr (Figure 3). In contrast, rottlerin produced no sig-
nificant inhibitory activity at 0.5 μM, and displayed an
IC50 at 48 hr of approximately 3 μM. LDH release assays
also showed greater than 10-fold increases in potency
for BJE6-106 compared to rottlerin (data not shown).
Inhibition of PKCδ prevents tumor sphere formation
Sphere formation assays, which have been commonly used
to identify and purify normal and malignant stem cells,
were used to select a “CSC-like population” from estab-
lished human breast cancer cell lines Hs578T, MDA231
and MCF7. A subpopulation of these cell lines could grow
as non-adherent spheres and be continuously propagated
in a defined serum-free medium in vitro. Flow cytometry
and immunofluorescence analysis indicated that sphere-Figure 3 Effects of a 3rd generation small molecule PKCδ inhibitor on
to 80% confluence in 96-well plates and then exposed to BJE6-106 at concen
ranging from 1 to 20 μM. The corresponding equivalent volume of solvent (D
exposure, cell mass was evaluated by MTT assay. Control values were normali
vehicle and rottlerin effects on cell number at 48 hr reached significance at 1
the 72 hr time point.derived cells from cell lines contained a much larger pro-
portion of cells expressing CD44, a candidate surface
marker of breast cancer stem cells, and/or a smaller pro-
portion of cells expressing the non-stem cell marker
CD24, compared with adherent cells (Figure 4A). The fre-
quency of spheroid formation relative to input cell num-
ber was low for the tumor cell lines (≤2-3%), as expected.
In contrast, spheroid formation from the cultures of pri-
mary PCSC or primary breast cancer stem cells (BCSC)
was much more efficient (45% and 53%, respectively). As
expected, the CD24/CD44 profiles of cells in the spheres
derived from the primary PCSC and BCSC did not differ
from the adherent cells (not shown).
Addition of rottlerin or BJE6-106 to the culture
medium very efficiently inhibited the formation of sphe-
roids from all of these cell types (Figure 4B), demon-
strating cytostatic or cytotoxic activity on tumor cells
having a CSC-like phenotype. Interestingly, the actions
of these compounds appeared to be even more potent
on the CSC subpopulation in the MCF7 cell line than on
the adherent “parental” cells (although different assays
are being compared). When the MCF7 adherent popula-
tion, containing predominantly non-CSC, was exposedhuman pancreatic cancer stem cell cultures. PCSC cells were grown
trations ranging from 0.1 to 20 μM, or to rottlerin at concentrations
MSO) was used as a vehicle control (Vehicle). After 48 and 72 hr of
zed to 100%. Error bars represent SEM. p values for comparison between
μM, and for BJE6-106 at 0.1 μM (p≤ 0.02), and remained significant at
A B
C D
Figure 4 (See legend on next page.)
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Figure 4 Effects of PKCδ inhibitors on human tumor cell spheroid formation. (A) Hs578T and MCF7 were plated under adherent or
non-adherent conditions. Tumor spheroids and adherent cells were collected at 96 hr, stained for CD24 and CD44, and analyzed by flow cytometry.
(B) Hs578T, MCF7, breast cancer stem cells (BCSC) and pancreatic cancer stem cells (PCSC) were plated in tumor spheroid media, in the presence of
rottlerin, BJE6-106, or DMSO (Control). Tumor spheroids were enumerated at 96 hr, and normalized to the number of spheroids in the control cultures
(assigned an arbitrary value of 100%). p values for comparison between vehicle and rottlerin or BJE6-106 effects were significant (p≤0.001). Photographs
are of representative areas of the culture plates. (C) MCF7 cells were exposed BJE6-106 or to rottlerin at the indicated concentrations. The corresponding
equivalent volume of solvent (DMSO) was used as a vehicle control (Vehicle). After 24, 48 and 72 hr of exposure, cell mass was evaluated by MTT assay.
Control values were normalized to 100%. p values for comparison between vehicle and rottlerin effects on cell number at 24 hr reached significance at
5 μM, and for BJE6-106 at 0.5 μM (p ≤ 0.02), and were significant for all concentrations tested at 48 and 72 hr time points. (D) Hs578T cells were
exposed to vehicle or BJE6-106 (1 μM) for 6, 12, 24, 48 or 96 hr. Viable cells were enumerated and re-plated in media without BJE6-206, and
spheroid numbers were quantitated 96 hr later. p values for comparison between vehicle and BJE6-106 effects on spheroid number were
significant after 6 hr of exposure (p≤0.02), and remained significant at all time points thereafter. Error bars represent SEM.
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10 μM and 1 μM, respectively, were required to repress
growth by more than 80% (Figure 4C). In contrast,
growth of MCF7 spheroids was inhibited greater than
90% by rottlerin at 10 μM and BJE6-106 at 1 μM. Wash-
out studies using spheroid formation demonstrated that
as little as 6 hr of exposure to BJE6-106 at 1 μM signifi-
cantly repressed spheroid formation of Hs578T cells,
with near maximum inhibition achieved by 24 hr of ex-
posure (Figure 4D).
In parallel studies, BJE6-106 at 0.5-1.0 μM and rottlerin
at 10 μM also efficiently inhibited the growth of tumor
spheroids generated from two human melanoma cell lines
(SBcl2, >99.5% inhibition, p < 0.001; FN5, >99.5% inhi-
bition, p < 0.001), two human pancreatic cancer cell lines
(MiaPaCa2, >97% inhibition, p < 0.001; Panc1, >99%
inhibition, p < 0.001); and two prostate cancer cell lines
(DU145, >98% inhibition, p < 0.001; PC3, >96% inhibition,
p < 0.001).
A CSC-like phenotype can be induced during epithe-
lial-mesenchymal transition (EMT) in transformed cell
lines. Transformation of the “normal” human mammary
epithelial cell line MCF 10A and selection for a tumori-
genic, metastatic phenotype in vivo produced the deri-
vative line MCF 10C [53,54], which exhibits an EMT
phenotype [60]. Cells of this malignant derivative also
became ALDH + [61]. Transformation of these cells ren-
dered them sensitive to rottlerin (Figure 5A) and to
BJE6-106 (Figure 5B), compared to the parental MCF
10A line. The IC50 of rottlerin and BJE6-106 for the
MCF 10C derivative was approximately 1 μM and
0.1 μM, respectively, at 72 hr, whereas the IC50 for the
parental MCF 10A cells were >20 μM.
The MCF 10C derivative also acquired the ability to
efficiently form non-adherent spheroids (Figure 5C), in
contrast to the parental MCF 10A cells. Growth of these
spheroids was efficiently inhibited by exposure to rottle-
rin at 10 μM or to BJE6-106 at 1 μM (Figure 5D and E).
The relative lack of toxicity of PKCδ inhibition on the
non-transformed, “normal” breast epithelial MCF 10A
cells is noteworthy, and further supports the establishednon-essential role of this isozyme in normal cells and
tissues. In other work, we have demonstrated that nor-
mal mouse embryo fibroblasts and human primary fibro-
blasts and epithelial cells and microvascular endothelial
cells and primary melanocytes survive and proliferate in
the setting of PKCδ knockdown or in concentrations of
PKCδ inhibitors which are lethal to tumor cell lines with
aberrant Ras signaling ([45-47,55]; Trojanowska et al., in
preparation).
Inhibition of PKCδ inhibits CSC tumor xenograft growth
Another property of CSCs is their high tumorigenic po-
tential. We therefore next sought to determine if PKCδ
inhibition would inhibit the growth of CSCs in vivo.
While the 3rd generation PKCδ inhibitory compounds
such as BJE6-106 are more potent and more cytotoxic to
tumor cells and CSCs than previous generations, they
have not been optimized for drug-like properties and are
highly hydrophobic and poorly bioavailable, making effi-
cient delivery of this generation of compounds in vivo
unreliable. We therefore tested a prior-generation PKCδ
inhibitor, rottlerin, which is readily bioavailable, in
a tumor model. The human breast cancer stem cell
(BCSC) cultures efficiently formed tumors as xenografts
in nude mice. In comparison to vehicle control, rottlerin
delivered intraperitoneally 5 days out of 7 effectively
inhibited the growth of the xenografts, even producing
tumor regression (Figure 6A). Survival was calculated on
the day when tumor size reached the predetermined
limit volume in the animals. The survival of the treated
cohort extended long beyond the treatment interval,
with some animals remaining tumor-free even at day
300 (Figure 6B).
We have previously demonstrated that depletion of
PKCδ is selectively toxic for cells with aberrant activa-
tion of Ras or Ras signaling pathways. Of the cell lines
and CSC studied in this report, only a minority bore
activating mutations of Ras itself (the pancreatic cancer
cells are K-Ras mutant, and the melanoma cells are
N-Ras mutant). MCF7 and the primary prostate and
breast cancer stem cells, for example, had normal Ras
Figure 5 (See legend on next page.)
Chen et al. BMC Cancer 2014, 14:90 Page 10 of 15
http://www.biomedcentral.com/1471-2407/14/90
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Figure 5 Effects of PKCδ inhibitors on growth and spheroid formation in non-transformed and transformed human breast epithelial
cells. MCF 10A cells and cells from the derived tumorigenic line MCF 10C (also called M3), were grown to 80% confluence in 96-well plates and
then exposed to rottlerin at concentrations ranging from 1 to 20 μM (A) or to BJE6-106 at concentrations ranging from 0.1 to 20 μM (B). The
corresponding equivalent volume of solvent (DMSO) was used as a vehicle control (Vehicle). After 24, 48 and 72 hr of exposure, cell mass was
evaluated by MTT assay. Control (vehicle) values were normalized to 100%. Error bars represent SEM. p values for comparison between vehicle
and PKCδ inhibitors on MCF 10A cell number only reached significance (p < 0.05) at 48 hr at 20 μM for rottlerin, and at 1 μM for BJE6-106. In
contrast, significant effects of the inhibitors on the MCF 10C cells were observed as early as 24 hr for rottlerin (at 5 μM) and for BJE6-106 (at 0.1 μM).
(C) MCF 10A and MCF 10C cells were plated at 10,000 cells per well in tumor spheroid media, and spheroid formation was assessed at days 10 and 21.
Representative photographs are shown. (D) MCF 10C cells were plated at 10,000 cells per well in tumor spheroid media, in the presence of rottlerin
(5 μM), or BJE6-106 (1 μM or 5 μM), or DMSO vehicle (Control). Tumor spheroids were enumerated at 10 days. Representative photographs are shown.
(E) Spheroid numbers were normalized to the number of spheroids in the control cultures (assigned an arbitrary value of 100%) and plotted. Error bars
represent SEM. p values for comparison between vehicle and rottlerin or BJE6-106 effects on spheroid number were significant (p < 0.001).
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rived from the CSCs, however, showed relative increases
of pERK or pAKT, compared to the respective parental
(adherent, non-spheroid) cells (Figure 7). These findings
indicate relative activation of the MEK/ERK pathway in
BCSC, MCF7 and Hs578T CSCs, and relative activation
of the PI3K-AKT pathway in MDA231 CSCs.
Discussion
Small populations of cancer cells within multiple types of
solid tumors have been identified based on cell surfaceA
B
Figure 6 Effects of PKCδ inhibitor on tumor growth and survival in a
stem cell xenografts were established and animals were treated with vehic
plotted over time, until tumors in all the control animals reached the maxi
(B) Kaplan-Meier plot of survival of vehicle control or rottlerin (PKCδi)-treate
at day 15.marker expression and other phenotypic and functional
characteristics. These subpopulations of tumor cells have
often demonstrated a >100-fold increase in tumorigenic
potential, compared to the remainder of the cells in the
tumor. Furthermore, tumors that form from these cancer
stem cells are indistinguishable from the human tumors
in which they originate, indicating that the tumor-
initiating cells are stem cell-like in their ability to self-
renew and give rise to a heterogeneous cell population.
Much recent data suggests that elimination of these can-
cer stem cells, which are typically resistant to conventionalxenograft human breast cancer stem cell model. Breast cancer
le or rottlerin for 15 days, as described in Methods. (A) Tumor volumes
mum volume allowed by the protocol (approximately 15 days).








1.0 3.2 8.1 2.7 5.2 3.4 5.8 2.7 1.2 2.3
1.0 1.1 3.8 2.5 3.2 2.4 2.6 1.1 1.5 1.0
1.0 2.3 0.8 1.2 2.4 2.4 2.2 2.2 0.4 4.5
1.0 2.4 0.8 1.6 4.8 2.0 1.1 1.3 2.0 1.2
1.0 2.0 1.1 3.1 0.9 0.7 1.3 0.5 0.6 0.6
1.0 4.3 8.7 7.2 8.4 3.9 9.4 2.0 2.7 1.6
Figure 7 Immunoblot analysis of Ras-signaling pathways in tumor cells, cell lines, or spheres. Hs578T, MCF7, MDA231 and breast cancer
stem cells (BCSC) were plated in tumor spheroid media under adherent or non-adherent conditions. Tumor spheroids and adherent cells were collected
at 96 hr, and lysed. MCF 10A (M1) and MCF 10C (M3) lysates were also prepared. The lysates were separated by electrophoresis and immunoblotted
with antibodies against ERK, pEKR, AKT, pAKT, JNK, pJNK. Immunoblotting of α-tubulin serves as a loading control. For quantitation, the digital intensity
of the bands was first normalized to α-tubulin in each lane, and then expressed relative to the signal for the MCF 10A (M1) cell line. Values are shown
under each band.
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ring solid tumors [1,4,5,32,33,35]. CSCs, or subclones
thereof, are the most likely perpetrators of invasion and
metastasis [6,62].
Recent findings have shown the existence of activated
and quiescent repertoires of stem cells in established
tumor cell lines as well as primary tumor cell isolates, and
their ability to interchange between these conditions [37].
Sphere-forming assays (SFA) are believed to evaluate the
differentiation and self-renewal capabilities of a tumor cell
population by assessing the potential of a tumor cell to be-
have like a stem cell, and are widely used in stem cell stud-
ies [37]. Sphere-forming assays have been commonly used
to retrospectively identify normal and cancer stem cells,
and measure stem cell/early progenitor activity in multiple
types of solid cancers [38,63,64]. Increased expression of
“stemness-related genes” [65] was observed when com-
paring solid tumor cell lines grown as 3D spheroids to
monolayers.
Our identification of PKCδ as a critical mediator of
survival in multiple types of solid tumors, including
prostate, breast, lung, pancreatic, neuroendocrine and
melanomas [45-48] raised the possibility that CSC popu-
lations might be similarly dependent upon the activity ofthis enzyme. The effects of PKCδ inhibition on CSCs,
however, had not been previously explored.
We first validated PKCδ as a target in diverse CSCs by
demonstrating here that specific and selective down-
regulation of PKCδ by shRNA was sufficient to prevent
the growth of human breast, pancreatic and prostate can-
cer stem-like cell cultures, and to induce cytotoxicity.
Potential therapeutic translation of this synthetic lethal
approach required the development of small molecule
probes. As no PKCδ-selective inhibitors had been deve-
loped to date, we initially used pharmacophore modeling
and docking of rottlerin, a well-established but not highly-
specific inhibitor of PKCδ, into the crystal structure of
PKCθ, to identify regions of the molecule important for
PKCδ-selectivity. The initial new molecule showing acti-
vity against PKCδ (KAM1) was formed by combining
structural elements of the broad spectrum protein kinase
inhibitor staurosporine and rottlerin. The chromene por-
tion of rottlerin was combined with the carbazole portion
of staurosporine to produce KAM1 [47]. KAM1 was
further modified to develop 36 new analogs, including
BJE6-106, which inhibits PKCδ with an IC50 value of 50
nM and is approximately 1000-fold selective versus PKCα.
Specificity for PKCδ over “classical” PKC isoforms, like
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toxic to all cells, normal and malignant, and would ren-
der these inhibitors non-“tumor-targeted”. We have
shown that B106 exerts potent cytotoxic activity against
N-Ras-mutant human melanomas and B-Raf-mutant
melanoma lines that have developed resistance to B-Raf
inhibitors by aberrant activation of alternative Ras sig-
naling pathways [48,55].
We demonstrate here that first, second and third gen-
eration PKCδ inhibitors (exemplified by rottlerin, KAM1
and BJE6-106, respectively), inhibit the growth of human
cancer stem-like cell cultures isolated from tumors, as
well as CSC-like cells derived from cell lines by spheroid
formation on non-adherent surfaces. Our prior studies
would have predicted that the CSC isolates or spheroids
derived from cell lines that contained activating muta-
tions of N-Ras or K-Ras would likely be susceptible to
PKCδ suppression (e.g., the K-Ras mutant pancreatic
carcinomas and the N-Ras mutant melanomas). The rea-
son for the susceptibility of the stem-like tumor cells
containing wt-Ras alleles, however, was not immediately
apparent. One reason for their susceptibility is likely to
be upregulation of Ras effector pathways (MEK-ERK or
PI3K/AKT signaling) in CSC spheres derived from cell
lines, compared to the non-CSC parental cultures. We
have reported previously that isolated activation of the
MEK-ERK effector pathway or the PI3K/AKT effector
pathway was sufficient to make cells dependent upon
PKCδ for survival [45-47]. The finding of higher levels
of Ras effector pathway activation in the CSC sphere
subpopulation compared to the parental cells may also
explain why in at least one instance (MCF7) the sphere-
forming CSC cells were substantially more susceptible to
PKCδ inhibition than non-CSC cells population. Inter-
estingly, a recent report has identified a requirement for
PKCδ in erbB2-driven proliferation of breast cancer cells
[66], and erbB2 drives aberrant Ras pathway signaling.
Furthermore, activation of MAPK pathways in basal-like
breast cancers has been reported to promote a cancer
stem cell-like phenotype [67], and activation of Ras/
MAPK signaling was reported to protect breast cancer
stem cells from certain stem-cell targeted drugs [68].
Collectively, these reports, together with our findings,
suggest that a PKCδ-targeted approach to breast cancer
stem cell populations, which exploits a synthetic lethal
interaction with aberrant Ras signaling, may be particu-
larly effective.
Inhibitory effects of PKCδ suppression on the IL6-
Stat3 axis, which is critical for CSC genesis or mainten-
ance in a number of tumor cells types [69-71], may also
contribute to the actions of PKCδ inhibition on CSC
growth and survival, and will be reported separately.
Epithelial-to-mesenchymal transition (EMT), induced
either by paracrine signaling from cancer-associatedfibroblasts (CAFs) or neighboring tumor cells, has been
associated with the acquisition of a stem cell phenotype
[72]. In culture, when immortalized normal or trans-
formed human mammary epithelial cells (HMECs) are
stimulated to undergo an epithelial-to-mesenchymal tran-
sition (EMT), the transition confers stem-like cell proper-
ties upon normal or transformed epithelial cells in culture,
partly because the cells acquire a CD44+/CD24 (low)
phenotype, similar to breast cancer stem cells.
The idea that cancer cells might reversibly transition
between epigenetically-defined tumorigenic and non-
tumorigenic states is of interest in part because mecha-
nisms that generate reversible heterogeneity can confer
resistance to therapies [73,74]. We took advantage of a
previously-established cell line model system for breast
cancer EMT, which consists of a parental spontaneously-
immortalized mammary epithelial cell line, MCF 10A
(M1), and one of its derivatives, MCF 10C (M3), derived
from a xenograft in nude mice that progressed to carci-
noma [53,54]. These cell lines were previously reported to
exhibit distinct tumorigenic properties when re-implan-
ted in nude mice; MCF 10A is non-tumorigenic, while
MCF 10C forms low-grade, well-differentiated carcinomas
[53,54,60]. Furthermore, MCF 10C has acquired pheno-
typic changes consistent with mesenchymal morphology
and gene and protein expression patterns characteristic
of EMT, including expression of mesenchymal markers
(fibronectin, vimentin, and N-cadherin) with concomitant
downregulation of E-cadherin, β-catenin, and γ-catenin.
MCF 10C also expresses high levels of Nanog, and Sox4,
which are markers of cancer stem cells [61]. We found
that the mesenchymal, CSC-like MCF 10C subline was
much more sensitive to PKCδ inhibitors than the
epithelial-like “normal” MCF 10A cells from which they
were derived. Furthermore, the MCF 10C line acquired
the capacity to efficiently form spheroids when grown in
non-adherent conditions, and this tumor spheroid forma-
tion was inhibited by inhibition of PKCδ activity.
Conclusions
Collectively, these findings suggest that human cancer
stem-like cells isolated from diverse sources and tumor
types require PKCδ activity for their growth or mainten-
ance in vitro and in vivo, making this isozyme a novel
tumor-specific target. Taken together with the previous
demonstration by our group and others of the cytotoxic
effects of PKCδ inhibition on the non-CSC population of
many tumor cell types, PKCδ inhibitors hold the promise
of eliminating both the majority non-CSC population and
the latent and resistant CSC population comprising hu-
man tumors.
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